-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

The Future Paradigm of HMA + ven or Targeted Inhibitor Approaches: Sequencing or Triplet Combinations in AML Therapy

Program: Education Program
Session: Have We Optimized Therapy Yet for Patients with AML?
Hematology Disease Topics & Pathways:
Research, clinical trials, Acute Myeloid Malignancies, AML, Clinical Research, Chemotherapy, Combination therapy, drug development, Diseases, Therapies, therapy sequence, Myeloid Malignancies
Sunday, December 10, 2023, 4:30 PM-5:45 PM

Justin M. Watts, MD

Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, MIAMI, FL

Disclosures: Watts: Rafael Pharma: Consultancy; Reven Pharma: Consultancy; Daiichi Sankyo: Consultancy; Celgene/BMS: Consultancy; Servier: Consultancy; Rigel: Consultancy, Research Funding; Aptose: Consultancy; Immune Systems Key, Ltd.: Research Funding; Takeda: Consultancy, Research Funding; Attivare: Consultancy.

OffLabel Disclosure: I will discuss approved indications and ongoing clinical trials, this may also off-label use of approved therapies when given in combination with each other

<< Previous Presentation | Next Presentation